Last reviewed · How we verify
Canagliflozin, 100 mg
At a glance
| Generic name | Canagliflozin, 100 mg |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Canagliflozin in Advanced CKD (PHASE4)
- Canagliflozin and Myocardial Fibrosis (PHASE4)
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer (PHASE2)
- Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer (PHASE1)
- Renal Mechanism of SGLT2 Inhibition (PHASE2)
- A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus (PHASE3)
- A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (PHASE3)
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canagliflozin, 100 mg CI brief — competitive landscape report
- Canagliflozin, 100 mg updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI